ReviewRMD open2019
The opioid epidemic: helping rheumatologists prevent a crisis.
Review in RMD open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Trial
- Identification of alkaline phosphatase as a putative biomarker of anti-NGF treatment-associated arthropathies: Machine learning-assisted analyses of clinical trial data.Osteoarthritis and cartilage open · 2026Article
- A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hip.Osteoarthritis and cartilage open · 2024Article
- Opioids and fibromyalgia: frequency of use and factors associated with increased consumption in patients remitted to a tertiary care center.BMC musculoskeletal disorders · 2024Observational
- Re-thinking the perception of long-term opioid use in RMDs.Nature reviews. Rheumatology · 2023Article
- Opioids for Osteoarthritis: Cross-Sectional Survey of Patient Perspectives and Satisfaction.Journal of clinical medicine · 2023Article
- Opioid Prescribing for Osteoarthritis: Cross-Sectional Survey among Primary Care Physicians, Rheumatologists, and Orthopaedic Surgeons.Journal of clinical medicine · 2023Article
- Anti-depressant medication use is a risk factor for incident knee surgery and opioid use in patients with knee osteoarthritis.Frontiers in psychiatry · 2023Article
- Cannabidiol as a treatment for arthritis and joint pain: an exploratory cross-sectional study.Journal of cannabis research · 2022Article
- Prevalence of Opioid Use Disorder among Patients with Cancer-Related Pain: A Systematic Review.Journal of clinical medicine · 2022Review
- Review
- Prescription of analgesics in patients with rheumatic diseases in Germany : A claims data analysis.Zeitschrift fur Rheumatologie · 2021Article
- [Prescription of analgesics in patients with rheumatic diseases in Germany : A claims data analysis. German version].Zeitschrift fur Rheumatologie · 2021Article
- Application of a crisis management nursing system in the novel coronavirus pneumonia epidemic.American journal of translational research · 2021Article
- Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain.Therapeutic advances in musculoskeletal disease · 2021Article
- Management of Osteoarthritis During the COVID-19 Pandemic.Clinical pharmacology and therapeutics · 2020Review
- East Midlands knee pain multiple randomised controlled trial cohort study: cohort establishment and feasibility study protocol.BMJ open · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An endemic increase in the number of deaths attributable to prescribed opioids is found in all developed countries. In 2016 in the USA, more than 46 people died each day from overdoses involving prescription opioids. European data show that the number of patients receiving strong opioids is increasing. In addition, there is an upsurge in hospitalisations for opioid intoxication, opioid abuse and deaths in some European countries. This class of analgesic is increasingly used in many rheumatological pathologies. Cohort studies, in various chronic non-cancer pain (CNCP) (osteoarthritis, chronic low back pain, rheumatoid arthritis, etc), show that between 2% and 8% of patients are treated with strong opioids. In order to help rheumatologists prescribe strong opioids under optimal conditions and to prevent the risk of death, abuse and misuse, recommendations have recently been published (in France in 2016, the recommendations of the French Society of Study and Treatment of Pain, in 2017, the European recommendations of the European Federation of IASP Chapters and the American Society of International Pain Physicians). They agree on the same general principles: opioids may be of interest in situations of CNCP, but their prescription must follow essential rules. It is necessary to make an accurate assessment of the pain and its origin, to formulate therapeutic objectives (pain, function and/or quality of life), to evaluate beforehand the risk of abuse and to get a specialised opinion beyond a certain dose or duration of prescription.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.